Q4 Earnings Estimate for COCP Issued By HC Wainwright

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Equities research analysts at HC Wainwright issued their Q4 2026 earnings per share estimates for shares of Cocrystal Pharma in a report released on Friday, October 9th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.15) for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($0.69) per share.

Separately, Weiss Ratings downgraded Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold”.

Cocrystal Pharma Stock Performance

NASDAQ:COCP opened at $1.08 on Monday. The stock has a 50-day simple moving average of $1.13 and a two-hundred day simple moving average of $1.14. The firm has a market capitalization of $20.80 million, a PE ratio of -1.42 and a beta of 1.48. Cocrystal Pharma has a 52-week low of $0.76 and a 52-week high of $2.03.

Cocrystal Pharma (NASDAQ:COCP) last released its earnings results on Thursday, August 13th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.06). The company had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.10 million.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc is a clinical-stage biotechnology company focused on discovering and developing antiviral therapies. The company uses a structure-based drug discovery platform to identify small-molecule compounds designed to interfere with essential viral replication proteins.

Its research programs have targeted a range of viral diseases, including influenza A, norovirus and coronaviruses. Cocrystal’s development activities have included orally administered antiviral candidates intended for the treatment or prevention of viral infections, with programs advancing through a combination of preclinical research and clinical development.

Founded in 2007 and formerly known as BioZone Pharmaceuticals, the company adopted the Cocrystal Pharma name after combining with Cocrystal Discovery in 2015.